^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment (clinicaltrials.gov)
    P3, N=400, Recruiting, Boehringer Ingelheim
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HER-2 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Hernexeos (zongertinib)
    1d
    A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) (clinicaltrials.gov)
    P2, N=147, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2026 --> Feb 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1410, Recruiting, Pfizer | N=387 --> 1410
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    1d
    BTCRC-LUN18-153: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm (clinicaltrials.gov)
    P2, N=244, Recruiting, Greg Durm, MD | Trial completion date: Apr 2029 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    KEYNOTE-D38: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC (clinicaltrials.gov)
    P2, N=63, Completed, IO Biotech | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Feb 2026 | Trial primary completion date: Jan 2024 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date • Pan tumor
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted)
    1d
    20230127: A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy (2023-508359-38-00)
    P2/3, N=84, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    HERIZON-BTC-302: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=286, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • gemcitabine • Ziihera (zanidatamab-hrii)
    1d
    Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Mar 2027
    Trial completion date
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • berzosertib (M6620)
    1d
    Iintune-1: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=248, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)
    1d
    GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Mayo Clinic | Suspended --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab)
    2d
    Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) (clinicaltrials.gov)
    P2, N=116, Not yet recruiting, Dana-Farber Cancer Institute
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    2d
    An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report. (PubMed, Cureus)
    Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel